EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme-Reference-Cited by-同舟云学术

EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme

Published:2013-02 Issue:2 Volume:23 Page:238-248
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Day Bryan W.,Stringer Brett W.,Al-Ejeh Fares,Ting Michael J.,Wilson John,Ensbey Kathleen S.,Jamieson Paul R.,Bruce Zara C.,Lim Yi Chieh,Offenhäuser Carolin,Charmsaz Sara,Cooper Leanne T.,Ellacott Jennifer K.,Harding Angus,Leveque Lucie,Inglis Po,Allan Suzanne,Walker David G.,Lackmann Martin,Osborne Geoffrey,Khanna Kum Kum,Reynolds Brent A.,Lickliter Jason D.,Boyd Andrew W.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference46 articles.

1. EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway;Aoki;J. Biol. Chem.,2004

2. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma;Balakrishnan;Cancer Res.,2007

3. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response;Bao;Nature,2006

4. Primary brain tumours in adults;Behin;Lancet,2003

5. Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell line;Boyd;J. Biol. Chem.,1992

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids;2024-08-03

2. EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses;Journal for ImmunoTherapy of Cancer;2024-08

3. EphA3 CAR T cells are effective against glioblastoma in preclinical models;Journal for ImmunoTherapy of Cancer;2024-08

4. Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity;Cell Communication and Signaling;2024-05-29

5. VIM-AS1, regulated by CpG methylation, cooperates with IGF2BP1 to inhibit tumor aggressiveness via EPHA3 degradation in hepatocellular carcinoma;2024-04-05